10 completed, 5 unknown, 2 terminated, 1 withdrawn. 18 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 10, Unknown 5, Terminated 2, Withdrawn 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Withdrawn 1 |
Follow Hypertrophy, Left Ventricular: new trials by email Literature Review of Hypertrophy, Left Ventricular trials Research Report on Hypertrophy, Left Ventricular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Valsartan, Placebo Oral Tablet - Aortic Valve Stenosis, Valsartan | Phase 2 / Phase 3 | Withdrawn | University Hospital, Limoges | 2023-01-02 | 2023-03-17 | |
| Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention SGLT2 inhibitor, Placebo - Aortic Stenosis, Left Ventricle Hypertrophied | Phase 2 / Phase 3 | Unknown | University of Aarhus | 106 | 2022-02-12 | 2022-02-15 |
| Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Perhexiline, Placebo marked PEXSIG - Myocardial Reperfusion Injury, Cardiac Output, Low | Phase 2 / Phase 3 | Unknown | University Hospital Birmingham | 220 | 2009-10-01 | 2011-08-11 |
| Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis ACE inhibitor Ramipril, non-RAS inhibitor antihypertensive therapy - Left Ventricular Hypertrophy, Hypertension | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 269 | 2009-05-01 | 2021-01-11 |
| The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL - Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | Phase 3 | Terminated | Abbott | 12 | 2009-01-01 | 2012-01-20 |
| Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis Atorvastatin 80 mg - Aortic Valve Stenosis, Ventricular Hypertrophy | Phase 3 | Unknown | University Hospital, Strasbourg, France | 60 | 2008-12-01 | 2015-06-19 |
| Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease spironolactone, placebo - Primary Hypertension | Phase 3 | Completed | University of Erlangen-Nürnberg Medical School | 50 | 2008-03-01 | 2012-07-10 |
| The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 paricalcitol, placebo - Chronic Kidney Disease, Left Ventricular Hypertrophy | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 227 | 2008-02-01 | 2013-03-12 |
| Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy Valsartan, Amlodipine, Hydrochlorothiazide - Hypertension; Hypertrophy, Left Ventricular | Phase 3 | Completed | Novartis | 90 | 2007-03-01 | 2011-05-11 |
| Stenting of Renal Artery Stenosis in Coronary Artery Disease Study stenting angioplasty plus medical therapy, Medical therapy - Renal Artery Stenosis, Left Ventricular Hypertrophy | Phase 3 | Unknown | Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele | 168 | 2006-04-01 | 2010-08-02 |
| Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis Candesartan - Aortic Valve Stenosis, Left Ventricular Hypertrophy | Phase 3 | Unknown | Odense University Hospital | 140 | 2006-02-01 | 2009-06-30 |
| Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Diltiazem, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 39 | 2006-01-01 | 2015-04-07 |
| Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo - Hypertension, Left Ventricular Hypertrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 460 | 2005-10-01 | 2011-05-26 |
| Hypertension in Hemodialysis Patients (Aim 3) Lisinopril, Atenolol - Hemodialysis, Hypertension | Phase 3 | Terminated | Indiana University | 200 | 2005-08-01 | 2016-01-18 |
| The CLEVER Study - Coreg And Left Ventricular Mass Regression carvedilol MR, atenolol, lisinopril - Hypertrophy, Left Ventricular | Phase 3 | Completed | GlaxoSmithKline | 287 | 2005-01-01 | 2016-12-16 |
| Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients ACE Inhibition, Intensified Blood Pressure Control, Add-on Angiotensin Receptor Blockade - Children, Chronic Renal Failure | Phase 3 | Completed | Heidelberg University | 400 | 1998-01-01 | 2010-01-12 |
| A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects. epoetin alfa - Anemia, Kidney Failure | Phase 3 | Completed | Janssen-Ortho Inc., Canada | 172 | 1997-12-01 | 2011-02-01 |
| Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years - Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) | Phase 3 | Completed | Organon and Co | 496 | 1995-06-01 | 2022-02-15 |
Hypertension (6) · Aortic Valve Stenosis (5) · Renal Insufficiency, Chronic (2) · Anemia (1) · Atrial Fibrillation (1) · Cardiac Output, Low (1) · Cardiomyopathy, Hypertrophic (1) · Cardiovascular Diseases (1) · Disease Progression (1) · Essential Hypertension (1) · Hypertrophy (1) · Kidney Failure, Chronic (1) · Myocardial Reperfusion Injury (1) · Overweight (1)
Cardiomegaly (18) · Heart Diseases (18) · Pathological Conditions, Anatomical (18) · Pathological Conditions, Signs and Symptoms (18) · Cardiovascular Diseases (17) · Hypertrophy (17) · Vascular Diseases (9) · Aortic Valve Disease (6) · Heart Valve Diseases (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Pathologic Processes (5) · Urogenital Diseases (5)
Atenolol (2) · Lisinopril (2) · Losartan (2) · Valsartan (2) · paricalcitol (2) · Amlodipine (1) · Atorvastatin (1) · Diltiazem (1) · Duration of Therapy (1) · Epoetin Alfa (1) · Hydrochlorothiazide (1) · Nutrition Therapy (1) · Perhexiline (1) · Ramipril (1) · Sodium-Glucose Transporter 2 Inhibitors (1)
AbbVie (prior sponsor, Abbott) (1) · Abbott (1) · Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele (1) · Brigham and Women's Hospital (1) · GlaxoSmithKline (1) · Heidelberg University (1) · Indiana University (1) · Janssen-Ortho Inc., Canada (1) · Mario Negri Institute for Pharmacological Research (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Odense University Hospital (1) · Organon and Co (1) · University Hospital Birmingham (1) · University Hospital, Limoges (1)
Germany (6) · Italy (6) · United States (6) · Czechia (3) · France (3) · Poland (3) · Russia (3) · Spain (3) · United Kingdom (3) · Australia (2) · Denmark (2) · Puerto Rico (2) · Romania (2) · Sweden (2) · Taiwan (2)
Ann Eldred, MD (1) · Carmelita Marcantoni, M.D. (1) · Carolyn Y Ho, MD (1) · Dennis Andress, MD (1) · Domeinco Pagano, MD FRCS (1) · Franz Schaefer, MD (1) · Henrik Nissen, MD, PhD (1) · Jacob E Moller, Md, Ph.D (1) · Jordi S Dahl, MD, MMSci (1) · Lars I Andersen, MD, DMSc (1)
PMID 18591942, PMID 14630977, PMID 14744931, PMID 15253732, PMID 15647341, PMID 15772249, PMID 16093916, PMID 16253719, PMID 19332468, PMID 20001655, PMID 20589977, PMID 20601389, PMID 21239405, PMID 21242674, PMID 21304095, PMID 21353251, PMID 21358415, PMID 21720264, PMID 21746765, PMID 22243363, PMID 22337679, PMID 22495466, PMID 22695506, PMID 22753219, PMID 22869821, PMID 23194491, PMID 23316326, PMID 23403268, PMID 24173271, PMID 24379001, PMID 24398888, PMID 24723582, PMID 25340854, PMID 26056336, PMID 26089332, PMID 26378687, PMID 27085434, PMID 27536421, PMID 27590665, PMID 29151037, PMID 29176391, PMID 29474712, PMID 29580174, PMID 30676480, PMID 32586143, PMID 32586346, PMID 33782036, PMID 35213289, PMID 35224730, PMID 35345262
2008 (1), K23HL078901 (1), R01DK062030 (1)